Rocket Pharmaceuticals (RCKT) Operating Expenses (2014 - 2026)

Rocket Pharmaceuticals has disclosed Operating Expenses across 13 years of filings, most recently posting $48.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $48.5 million, down 24.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $215.9 million (down 20.11% YoY), and the FY2025 annual result was $231.7 million, down 15.17% from the prior year.
• Operating Expenses came in at $48.5 million for Q1 2026 at Rocket Pharmaceuticals, up from $44.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $73.7 million in Q2 2024 to a low of $42.6 million in Q1 2022.
• The 5-year median for Operating Expenses is $63.3 million (2023), against an average of $61.0 million.
• Across the five-year window, Operating Expenses jumped 59.22% in 2022 and fell 29.88% in 2025, its largest moves.
• Rocket Pharmaceuticals' Operating Expenses stood at $69.1 million in 2022, then declined by 8.4% to $63.3 million in 2023, then fell by 0.92% to $62.7 million in 2024, then dropped by 29.88% to $44.0 million in 2025, then increased by 10.35% to $48.5 million in 2026.
• The last three Operating Expenses figures came in at $48.5 million (Q1 2026), $44.0 million (Q4 2025), and $52.2 million (Q3 2025), per Business Quant data.